anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The investigators plan to recruit the patients who were pathologically confirmed with esophageal squamous cell carcinoma or gastric cardia adenocarcinoma from the Oct.2015. The patients will be divided into two groups. Group 1: Following intravenous administration of photofrin at dose of 2 mg/kg.b.w. as the photosensitizer, 630 nm laser irradiation (DIOMED) with 400 mW/cm was applied on each part of tumor for 750 seconds through cylinder diffusing quartz fibers localizing in the biopsy channel of a flexible endoscope at 24th. Group 2: Following intravenous administration of photofrin at dose of 2 mg/kg.b.w. as the photosensitizer, 630 nm laser irradiation (DIOMED) with 400 mW/cm was applied on each part of tumor for 750 seconds through cylinder diffusing quartz fibers localizing in the biopsy channel of a flexible endoscope at 48th.
BACKGROUND & AIMS: The cost-effectiveness to screen hepatic fibrosis in at-risk population as recommended by several professional societies has been limited. This study aimed to investigate the cost-effectiveness of this screening strategy in the expanded at-risk population recently proposed by several societies.
METHODS: A combined model of the decision tree and Markov models was developed to compare expected costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (ICER) between screening and no screening groups. The model included liver disease-related health states and cardiovascular disease (CVD) states as a base-case analysis. Screening strategy consisted of fibrosis-4 index (FIB-4) followed by vibration-controlled transient elastography (VCTE) and intensive lifestyle intervention (ILI) as a treatment for diagnosed patients.
RESULTS: Cost-effectiveness analysis showed that screening the at-risk population entailed $298 incremental costs and an additional 0.0199 QALY per patient compared to no screening (ICER $14 949/QALY). Screening was cost-effective based on the implicit ICER threshold of $25 000/QALY in Korea. When the effects of ILI on CVD and extrahepatic malignancy were incorporated into the cost-effectiveness model, the ICER decreased by 0.85 times from the base-case analysis (ICER $12 749/QALY). In contrast, when only the effects of liver disease were considered in the model, excluding cardiovascular disease effects, ICER increased from the baseline case analysis to $16 305. Even when replacing with medical costs in Japan and U.S., it remained cost-effective with the estimate below the countries' ICER threshold.
CONCLUSIONS: Our study provides compelling evidence supporting the cost-effectiveness of FIB-4-based screening the at-risk population for advanced hepatic fibrosis.
The invention discloses a traditional Chinese medicine foot bath preparation prepared by utilizing microbial fermentation and a preparation method thereof and belongs to the field of parenteral administration preparations. The preparation method includes: placing brewer's yeast, candida utilis and lactobacillus reuteri in a water solution of ginkgo leaf extract, algae powder, menthol, baking soda, edible salt and glucose at 37-40 DEG C for anaerobic cultivation to obtain microbial fermentation foot bath preparation engineering bacterium liquid. The bacterium liquid is adopted for fermenting compound traditional Chinese medicine. The ginkgo leaf extract has promoting effect on expanding pores and blood vessels and increasing administration speed, menthol has transdermal efficacy and can improve permeability of drug in a plantar dermis layer and a cuticle layer, density of foot bath liquid prepared by baking soda, edible salt and glucose is greater than that of body fluid, so that osmotic pressure of the foot bath liquid is increased. Toxic and harmful substances in the compound traditional Chinese medicine are degraded after fermentation, and absorbing effect of traditional Chinese medicine activity agent is improved by utilizing synergistic effect of beneficial bacteria and active ingredients of the traditional Chinese medicine. The traditional Chinese medicine foot bath preparation is effective in disease dispelling, healthcare and scientific administration.
PURPOSE:To obtain an intraocular pressure depressing agent containing specific prostaglandins as active ingredients and effective in remedy for glaucoma without accompanying side effects such as afflux, closure of eye and flowing of tear. CONSTITUTION:The aimed intraocular pressure depressing agent containing prostaglandins (hereinafter referred to as PGs) wherein carbon atom in 20 position is substituted by a hydrocarbon group as active ingredients. PGs are based on basic skeleton expressed by formula I and e.g., PGA1s, PGA2s, PGA3s, PGB1s. Intraocular pressure depressing action of PGs is especially remarkable in PGs expressed by formula II (A is PGA1 expressed by formula III; Y is 2-6C hydrocarbon chain, etc.; Z is 1-10C aliphatic hydrocarbon, etc.) and salt thereof or PGs whose carboxyl groups are esterified.
During ureteroscopic treatment for ureteral stones, lithotripsy, irrigation, and manipulation of the stone often pushes stone away into the kidney itself. This phenomenon is called retropulsion, which is defined as clinically significant retrograde migration of stone or stone fragments. Movement of stones retrograde into the renal pelvis could potentially add and complicate the surgery further. Often scopes need to be changed in order to reach the stone, and chasing these stones will add time to the surgery and require more valuable resources. Furthermore, sometimes a second operation will need to be done when these retropulsed fragments could not be all found and cleaned out.

A number of devices have been developed to prevent such migration including stone baskets and conical devices. These are wire-based devices which have the potential of injuring the ureter. Because of safety concerns and that there is limited data available on the effectiveness of these devices; these are not widely used by urologists. BackStop has recently been developed as another tool to prevent retropulsion. It is a water soluble gel that is injected proximal to the stone. This creates a physical barrier that prevents stone migration during ureteroscopic lithotripsy for ureteral calculus.
Varicose veins are highly prevalent. In western countries, an estimated 23% of adults have varicose veins, and 6% have more advanced chronic venous disease, including skin changes and healed or active venous ulcers. There are several modalities to treat varicose veins. Open surgical treatment with ligation and stripping of the saphenous vein, combined with excision of large varicosities, has been the standard of care for many years. Endovenous thermal ablation by radiofrequency ablation (RFA) or endovenous laser ablation (EVLA) has been shown to be a safe and effective alternatives with high long-term target vein closure rates. Although both techniques have gained broad acceptance in many countries, one major disadvantage of these techniques is the requirement for use of tumescent anesthesia to avoid the thermal injury of the surrounding structures. Cyanoacrylate closure for varicose veins has recently been introduced for treatment of the incompetent saphenous vein.
A composition comprising lactoferrin for treating and/ or preventing 2019 coronavirus (COVID-19) infection in a subject. The daily dosage can be between 1 mg/day to about 50 g/day. The composition can be a nutritional composition. The composition can be intended for a paediatric subject or an adult. The composition can be a synthetic composition. The composition can comprise at least one of or a combination of an excipient, a binder, a disintegrant, a diluent, a glidant, a solubilizer, a lubricant, a flavouring agent.
PROBLEM TO BE SOLVED: To effectively utilize the nuclides of a short half-life for the medical inspection in the positron emission type computer tomography(CT) and the system therefor. SOLUTION: The nuclide (18F) 13 is produced by means of the cyclotron 2 in the hospital facilities 1. Additionally, inspection devices 5 and the synthesis devices 3, 4 are installed in combination in the hospital facilities. The nuclide 13 is used as a starting material for synthesizing the chemical for the positron emission type CT in the synthesis device 4 and the chemical is transferred to the inspection devices 5. The excessive nuclides 13 may be supplied to other hospital facilities 14, 25. Chemical-synthesizing devices 26, 27 are arranged in the hospital facilities 14, 25 the chemicals for the positron emission type CT are synthesized by means of individual synthesizers. The process time for these chemicals are calculated based on the half-life period of these nuclides and controlled and are served for the positron emission type CT in individual hospital facilities.
The treatments for people with apical HCM and symptoms are limited but include medicines. The use of a pacemaker in this situation is an experimental treatment which has not yet been fully explored. We believe symptoms are linked with abnormalities in blood flow through the heart muscle at the tip / apex of the heart and wish to see if using a pacemaker can improve such abnormalities. We want to test if this treatment works using a clinical trial to help us decide whether this is a viable treatment option that may be offered to other patients with the condition. The null hypothesis states that there will be no difference in blood flow through the heart muscle with pacing. The alternative hypothesis states that there will be a significant difference in blood flow through the heart muscle with pacing. This was chosen based upon our current knowledge that abnormal blood flow in the heart muscle in apical HCM is linked with abnormal squeeze at the apex / tip and symptoms. Echocardiography pilot data has demonstrated a reduction in squeeze at the apex of the heart when using the pacemaker to cause the heart muscle to contract in a different way.

Our alternative hypothesis therefore is that we can use the pacemaker to reduce squeeze at the apex and improve blood flow through the heart muscle. This is a single centre, prospective pilot study. Because data on acute changes in perfusion with pacing in apical HCM are extremely limited, the most ethical methodology is to perform a two-phase study. Phase A of the study assesses acute changes in blood flow through the heart muscle during different pacemaker settings (active and back-up), looking for potential efficacy of the intervention. Secondary outcomes of Phase A include recruitment rate and proportion of patients willing to proceed to Phase B. Phase B of the study consists of entering those same patients into a randomised double-blind cross-over 6-month follow-up pilot to collect baseline statistical data and assess acceptability of study protocol to design a future study. Here, assessment of further secondary outcomes will allow establishment of baseline statistical data for the design of an outcomes-based clinical trial. Patients will only be entered into phase B of the study if an improvement is seen in myocardial perfusion with pacing during phase A.
Placenta accreta spectrum (PAS) can be associated massive intra- and post-operative hemorrhage which when not controlled can lead to maternal death. Important advances have occurred in understanding the pathophysiology and therapeutic options for this condition. The prevalence of PAS at birth is direct association with the cesarean delivery (CD) rate in the corresponding population and is increasing worldwide. Limited health infrastructure in low- and middle-income countries increases the morbidity and mortality of patients with PAS at birth. In many cases, obstetricians working in limited resources settings cannot follow some of the international guideline's recommendations and have to opt for low-cost management procedures. In this review, we describe the particularities of managing PAS care in low- and middle-income countries from of prenatal evaluation of patients at risk of PAS at birth, therapeutic options, and inter-institutional collaboration. We also propose a management protocol based on training of the local obstetric teams rather than on sophisticated technological resources that are almost never available in low-resource scenarios.
BACKGROUND: The impact of coronavirus disease 2019 (COVID-19) on postoperative recovery from oncology surgeries should be understood for the clinical decision-making. Therefore, this study was designed to evaluate the postoperative cumulative 28-day mortality and the morbidity of surgical oncology patients during the COVID-19 pandemic.
METHODS: This retrospective cohort study included patients consecutively admitted to intensive care units (ICU) of three centres for postoperative care of oncologic surgeries between March to June 2019 (first phase) and March to June 2020 (second phase). The primary outcome was cumulative 28-day postoperative mortality. Secondary outcomes were postoperative organic dysfunction and the incidence of clinical complications. Because of the possibility of imbalance between groups, adjusted analyses were performed: Cox proportional hazards model (primary outcome) and multiple logistic regression model (secondary outcomes).
RESULTS: After screening 328 patients, 291 were included. The proportional hazard of cumulative 28-day mortality was higher in the second phase than that in the first phase in the Cox model, with the adjusted hazard ratio of 4.35 (95% confidence interval [CI] 2.15-8.82). The adjusted incidences of respiratory complications (odds ratio [OR] 5.35; 95% CI 1.42-20.11) and pulmonary infections (OR 1.53; 95% CI 1.08-2.17) were higher in the second phase. However, the adjusted incidence of other infections was lower in the second phase (OR 0.78; 95% CI 0.67-0.91).
CONCLUSIONS: Surgical oncology patients who underwent postoperative care in the intensive care unit during the COVID-19 pandemic had higher hazard of 28-day mortality. Furthermore, these patients had higher odds of respiratory complications and pulmonary infections. Trials registration The study is registered in the Brazilian Registry of Clinical Trials under the code RBR-8ygjpqm, UTN code U1111-1293-5414.
The invention discloses a suspension for making an adipose derived stem cell. The suspension can be used for preparing an injection, and the injection can be used for treating erectile dysfunction of male animals including humans and is especially suitable for treating erectile dysfunction of the male animals including humans due to diabetes. The adipose derived stem cell (ADSC) is an adult stem cell having multidirectional differentiation potential, has the advantages of easiness in material taking, simplicity in culture and quickness in proliferation and becomes an important seed cell in regenerative medicine. Unexpectedly, experimental studies find that after the suspension of the adipose derived stem cell is injected to the root of the penis of a male animal, erectile dysfunction of the male animal can be improved effectively. The adipose derived stem cell can be obtained from animals or humans to be treated, so that operation complexity can be reduced, and biological rejection can be prevented to a certain degree. Erectile dysfunction disease of the male animals can be treated by transplanting the adipose derived stem cell, and in essence, a new transplanting direction is provided for the adipose derived stem cell.
INTRODUCTION: Cyanotic congenital heart diseases constitute 40-45% of all congenital heart diseases. In patients who are not suitable for primary repair, modified BT (MBT) shunt and central shunt (CS) procedures are still frequently used.
METHODS: This study included 62 pediatric patients who underwent MBT shunt or CS via median sternotomy. Patients' demographic, echocardiographic, operative, and postoperative data were collected retrospectively. The patients were classified as single ventricle and bi-ventricle according to their cardiac anatomy, and the presence of prematurity and heterotaxy was noted. Procedure details of the patients who underwent endovascular intervention prior to the surgery were investigated, and operation data were accessed from the surgery notes. Data regarding postoperative follow-ups were obtained and comparatively analyzed.
RESULTS: Of the total 62 patients, 32 (51.6%) were newborns and 16 (25.8%) had a body weight < 3 kg. MBT shunt was applied to 48 patients (77.4%), while CS was applied to 14 patients (22.6%). There was no significant difference between the two surgical procedures in terms of requirement for urgent shunt or cardiopulmonary bypass, additional simultaneous surgical intervention, need for high postoperative inotropes, and in-hospital mortality (P>0.05). The rate of congestive heart failure in patients with in-hospital mortality was determined as 66.7% and it was significantly higher than in patients without heart failure (P<0.001).
CONCLUSION: MBT shunt and CS are still frequently used in cyanotic patients. The use of small-diameter shunts, particularly when centrally located, can prevent the onset of congestive heart failure and lower mortality.
The present invention provides a method of controlling levels/concentrations of a target moiety. The method of the present invention includes introducing into a cell a product comprising at least one of each of the following modules: a targeting module, a destruction module and a replacement module. The method further comprises targeting the target moiety with the targeting module so that the destruction module can effect degradation of the target moiety and replacing the target moiety with a replacement: module. The replacement module may be either a modified form of the target moiety itself or a functional unit which restores normal metabolic activity of the cell. The present invention also a destruction module and a replacement module, nucleic acids encoding the products and vectors. The present invention also provides for use of the method and products in treating various clinical disorders.
Participants receiving the Art of Medicine Series will be sent text messages throughout the 4 week study intervention period. Each text message contains a link to a short, animated video teaching an evidence-based communication technique.
For details on the preparation and administration of NORVIR oral powder (see Instructions for Use). NORVIR oral powder should only be used for dosing increments of 100 mg.

Prepare the dose using the required number of packets. For example, use one packet for doses of 100 mg and two packets for doses of 200 mg. Pour and mix the entire contents of each packet over soft food or liquid. All of the powder mixed with soft food or liquid should be administered within 2 hours of preparation. If not administered within 2 hours of preparation, the mixture should be discarded and a new dose prepared.

The prescribed dose of NORVIR oral powder can be administered via a feeding tube after being mixed with water (see Instructions for Use). Follow the instructions for the feeding tube to administer the medicine.
This study will involve about 18 visits over 2½ years for specific tests of the participant's vision and health. These visits may include visual exams, blood draw for laboratory testing, brief medical history and exam, and occasionally a questionnaire (survey), in addition to the visit for the surgical procedures. The primary effectiveness outcome for this study will be a visual field score one year after the implant surgery. There will be about 12 centers participating in this study, and up to 60 people enrolled, across the US. Each participant joining the study who has completed initial screening will then be scheduled to have a brief surgical procedure performed on each eye, one of which will include a very small cell-filled implant. Follow-up visits for repeat assessments will be required regularly to determine if the implant being tested is safe and effective for use to treat retinitis pigmentosa (RP).
FABIOR Foam is contraindicated in pregnancy [see Contraindications (4)].

There are no adequate and well-controlled studies with FABIOR Foam in pregnant women. FABIOR Foam is contraindicated in females who are or may become pregnant [see Contraindications (4)]. Females of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when FABIOR Foam is used. The possibility that a female of child-bearing potential is pregnant at the time of institution of therapy should be considered. A negative serum or urine result for pregnancy test having a sensitivity down to at least 25 mIU/mL for hCG should be obtained within 2 weeks prior to therapy with FABIOR Foam, which should begin during a normal menstrual period for females of childbearing potential.

In rats, tazarotene 0.05% gel administered topically during gestation days 6 through 17 at 0.25 mg/kg/day resulted in reduced fetal body weights and reduced skeletal ossification. Rabbits dosed topically with 0.25 mg/kg/day tazarotene gel during gestation days 6 through 18 were noted with single incidences of known retinoid malformations, including spina bifida, hydrocephaly, and heart anomalies.

Systemic exposure (AUC) to tazarotenic acid at topical doses of 0.25 mg/kg/day tazarotene in a gel formulation in rats and rabbits were 15 and 166 times, respectively, the AUC in acne patients treated with 2 mg/cm2 of FABIOR Foam 0.1% over a 15% body surface area.

As with other retinoids, when tazarotene was administered orally to experimental animals, developmental delays were seen in rats, and teratogenic effects and post-implantation loss were observed in rats and rabbits at doses 13 and 325 times, respectively, the AUC to tazarotenic acid in acne patients treated with 2 mg/cm2 of FABIOR Foam 0.1% over a 15% body surface area.

In female rats orally administered 2 mg/kg/day tazarotene from 15 days before mating through gestation day 7, a number of classic developmental effects of retinoids were observed including decreased number of implantation sites, decreased litter size, decreased numbers of live fetuses, and decreased fetal body weights. A low incidence of retinoid-related malformations was also observed. AUC in rats was 42 times the AUC in acne patients treated with 2 mg/cm2 of FABIOR Foam 0.1% over a 15% body surface area.
Adolescents at study clinics who score low or intermediate on transition readiness during screening will be invited to enroll in the study. Adolescents attending clinics randomized to the in-person supported adolescent friendly services will attend their clinic after school hours on a designated day or on weekends dedicated for adolescent care monthly for 9 months.
Directions for Mixing Oral Suspension 

Prepare a suspension at time of dispensing as follows: 

Tap bottle until all powder flows freely. Measure the total amount of water (see chart below) to be added in two parts. Add approximately 2/3 of the total amount of water for reconstitution, replace cap and shake vigorously to suspend powder. Add remainder of the water (that had been measured), replace cap and again shake vigorously.

Each teaspoonful (5 mL) will contain 600 mg of amoxicillin as the trihydrate and 42.9 mg of clavulanic acid as the potassium salt.

Shake oral suspension well before each use. Suspension must be refrigerated. Discard after 10 days. Suspension is white to yellow at time of reconstitution; some color change is normal during the dosing period.
The patient will receive a 24-hour course of antibiotics. The primary antibiotic of choice will be cefazolin 1 gm iv q8 hours. If the patient has contraindications to the use of cefazolin including cefazolin allergy, hypersensitivity, or severe beta lactam allergy, then clindamycin 900 mg iv q8 hours will be used instead.